UBS Downgrades GlaxoSmithKline (GSK) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
UPDATE: UBS Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Sell
November 11, 2022 5:27 AM EST(Updated - November 11, 2022 7:55 AM EST)
UBS analyst Michael Leuchten downgraded GlaxoSmithKline (GSK:LN) (NYSE: GSK) from Neutral to Sell with a price target of GBP13.00 (from GBP18.20).
The analyst commented, "At face value GSK trades on c9x... More
European stocks edge lower; earnings season in full flow
November 10, 2022 5:23 AM EST
By Peter Nurse
Investing.com - European stock markets traded marginally lower Thursday, with turmoil in the crypto market dampening sentiment while investors continued to digest U.S. midterm elections as well as quarterly corporate results.
At 03:55 ET (08:55 GMT), the DAX index in Germany traded 0.1% lower, CAC 40 in France fell 0.4% and the FTSE 100 in the U.K. dropped 0.1%.
The U.S. political climate remained uncertain Thursday, two days after the midterm elections, with Republicans edging closer to securing a majority in the... More
